Isatuximab SAR650984: Pharmaceutical for: Solution for infusion Route of administration: Intravenous
Lenalidomide: Pharmaceutical form: Capsules Route of administration: Oral
Dexamethasone: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
Montelukast or equivalent: Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
Acetaminophen: AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
Diphenhydramine or equivalent: AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
Methylprednisolone or equivalent: AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
Study summary
Primary Objectives:
* Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
* Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM
Secondary Objectives:
Safety run-in Part:
* To assess overall response rate (ORR)
* To assess duration of response (DOR)
* To assess minimal residual disease (MRD) negativity in participants achieving very good partial response (VGPR) or complete response (CR)
* To assess time to diagnostic (SLiM CRAB) progression or death
* To assess time to first-line treatment for multiple myeloma (MM)
* To assess the potential immunogenicity of isatuximab
* Impact of abnormal chromosomal subtype on participant outcome
* CR rate
* ORR
* DOR
* Time to diagnostic (SLiM CRAB) progression
* Time to biochemical progression
* Time to first-line treatment for MM
* Impact of abnormal chromosomal subtype on participant outcome
* Safety and tolerability
* Pharmacokinetics (PK)
* Potential of isatuximab immunogenicity
* Clinical outcome assessments (COAs)
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria:
* Participants who are diagnosed within 5 years with SMM (per International Myeloma Working Group \[IMWG\] criteria), defined as serum M-protein ≥30 g/L or urinary M-protein ≥500 mg per 24 hour or both, and/or clonal bone marrow plasma cells (BMPCs) 10% to \<60%, and absence of myeloma defining events or other related conditions and with high-risk SMM
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 or 2
* Capable of giving voluntary written informed consent
* Absolute neutrophil count (ANC) ≥1000/µL (1 × 10\^9/L)
* Platelets ≥50,000/µL (50 × 10\^9/L)
* Total bilirubin ≤3 mg/dL (except Gilbert syndrome, in which direct bilirubin should be -≤5 mg/dL).
* Alanine aminotransferase ≤3× upper limit of normal (ULN), aspartate aminotransferase ≤ 3 × ULN.
Exclusion criteria:
* Evidence of any of the following calcium, renal failure, anemia, bone lesions (CRAB) criteria or Myeloma Defining Events (SLiM CRAB) detailed below (attributable to the participants SMM involvement):
* Increased calcium levels: Corrected serum calcium \>1 mg/dL above the ULN or \>11 mg/dL
* Renal insufficiency: Determined by glomerular filtration rate (GFR) \<40 mL/min/1.73 m² (Modification of Diet in Renal Disease \[MDRD\] Formula) or serum creatinine \>2 mg/dL
* Anemia (hemoglobin 2 g/dL below lower limit of normal or \<10 g/dL or both) transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted
* ≥ 1 bone lytic lesion
* BMPCs ≥60%
* Serum involved/uninvolved FLC ratio ≥100 and an involved FLC ≥100mg/L
* Whole body magnetic resonance imaging (WB-MRI) or positron emission tomography-computed tomography (PET-CT) with more than 1 bone focal lesion (≥5 mm in diameter by MRI)
* Primary systemic amyloid light-chain (AL) amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), standard risk smoldering myeloma, soft tissue plasmacytoma, symptomatic myeloma
* Uncontrolled infection within 28 days prior to randomization in Phase 3 or first study intervention administration in safety run-in
* Clinically significant cardiac or vascular disease within 3 months prior to randomization, e.g. Myocardial Infarction; Unstable Angina; Coronary (e.g. Coronary Artery Bypass Graft, Percutaneous Coronary Intervention) or peripheral artery revascularization, Left Ventricular Ejection Fraction \<40%, Heart Failure NYHA III-IV, Stroke, Transient Ischemic Attack, Pulmonary Embolism, other thromboembolic event, cardiac arrhythmia (Grade 3 or higher by NCI-CTCAE Version 5.0)
* Known acquired immunodeficiency syndrome (AIDS)-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A (defined as positive hepatitis A antigen or positive IgM). HIV serology at screening will be tested for German participants and any other country where required as per local regulations and serology hepatitis B and C at screening will be tested for all participants
* Uncontrolled or active hepatitis B virus (HBV) infection: Patients with positive Hepatitis B surface antigen (HBsAg) and/or HBV Deoxyribonucleic acid (DNA)
Of note:
* Patient can be eligible if anti-HBc Immunoglobulin G (IgG) positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative. If anti-HBV therapy in relation with prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.
* Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative and all the other study criteria are still met.
* Active hepatitis C virus (HCV) infection: positive HCV ribonucleic acid (RNA) and negative anti-HCV
Of note:
* Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.
* Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible
* Malabsorption syndrome or any condition that can significantly impact the absorption of lenalidomide
* Any of the following within 3 months prior to randomization (or first study intervention administration in safety run-in cohort): treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event
* Received treatment (eg surgery, radiotherapy, medication) for a malignancy within 3 years of randomization (or first study intervention administration in safety run-in cohort)
* Prior exposure to approved or investigational treatments for SMM or multiple myeloma (MM) (including but not limited to conventional chemotherapies, immunomodulatory imid drugs, or Proteasome inhibitors); concurrent use of bisphosphonates or receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permitted
* Ongoing treatment with corticosteroids with a dose \>10 mg prednisone or equivalent per day at the time of randomization (or first study intervention administration in safety run-in cohort)
* Women of childbearing potential or male participant with women of childbearing potential who do not agree to use a highly effective method of birth control
* Vaccination with a live vaccine 4 weeks before the start of the study drug. Seasonal flu vaccines that do not contain live virus are permitted
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Primary outcome measure(s)
Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events- Safety Run-in Part — Up to approximately 63 months
Plasma concentration of isatuximab during the treatment period - Safety Run-in Part — After first infusion from Cycle 1 Day 1 to Day 28 in safety run-in part
Receptor density/receptor occupancy Safety Run-in Part — Baseline to Cycle 2 Day 1 (each cycle is 28 days) Change in CD38 receptor occupancy from baseline
Progression-free survival (PFS) Randomized Phase 3 Part — Up to approximately 114 months PFS defined as the time from randomization to MM (SLiM CRAB criteria) or other related conditions based on independent review committee (IRC) assessment according to 2014 International Myeloma Working Group (IMWG) criteria or death from any cause, whichever happens first
Trial sites (105)
Facility
City
Region
Status
UCLA Site Number : 8400010
Los Angeles
California
Colorado Blood Cancer Institute Site Number : 8400007
Denver
Colorado
Cancer Specialist of North Florida Site Number : 8400011
Jacksonville
Florida
University of Miami Site Number : 8400012
Miami
Florida
Dana Farber Cancer Institute Site Number : 8400001
Boston
Massachusetts
Presbyterian Hospital Site Number : 8400015
Charlotte
North Carolina
Novant Health Forsyth Medical Center Site Number : 8401015
Winston-Salem
North Carolina
Tennessee Oncology Site Number : 8400006
Nashville
Tennessee
~University of Texas - MD Anderson Cancer Center Site Number : 8400002
Houston
Texas
Investigational Site Number :0360008
Liverpool
New South Wales
Investigational Site Number :0360005
Waratah
New South Wales
Investigational Site Number :0360001
Wollongong
New South Wales
Investigational Site Number :0360002
Fitzroy
Victoria
Investigational Site Number :0360007
Heidelberg West
Victoria
Investigational Site Number :0360004
Richmond
Victoria
Investigational Site Number :0360006
Nedlands
Western Australia
Investigational Site Number :0760002
São Paulo
São Paulo
Investigational Site Number :1240004
Edmonton
Alberta
Investigational Site Number :1240005
Moncton
New Brunswick
Investigational Site Number :1240001
Montreal
Quebec
Investigational Site Number :1560002
Hangzhou
China
Investigational Site Number :1560003
Hangzhou
China
Investigational Site Number :1560006
Nanchang
China
Investigational Site Number :1560004
Shanghai
China
Investigational Site Number :1560005
Shenyang
China
Investigational Site Number :1560001
Tianjin
China
Investigational Site Number : 2030004
Brno
Czechia
Investigational Site Number : 2030005
Hradec Králové
Czechia
Investigational Site Number : 2030002
Olomouc
Czechia
Investigational Site Number : 2030003
Ostrava - Poruba
Czechia
Investigational Site Number : 2030001
Prague
Czechia
Investigational Site Number :2080001
Aalborg
Denmark
Investigational Site Number :2080003
Aarhus N
Denmark
Investigational Site Number :2080005
Copenhagen
Denmark
Investigational Site Number :2080002
Roskilde
Denmark
Investigational Site Number :2500009
Ars-Laquenexy
France
Investigational Site Number :2500010
Bayonne
France
Investigational Site Number :2500007
Grenoble
France
Investigational Site Number :2500006
La Roche-sur-Yon
France
Investigational Site Number :2500003
Lille
France
+ 65 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.